Related Experiment Video

Updated: Jun 11, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Clinical development of phosphatidylinositol-3 kinase pathway inhibitors

Carlos L Arteaga1

  • 1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. carlos.arteaga@vanderbilt.edu

Current Topics in Microbiology and Immunology
|July 2, 2010
PubMed

Insights

The PI3K pathway is frequently altered in cancer. PI3K inhibitors show promise in clinical trials, with further research needed to optimize their use and identify effective patient populations and combinations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase (PI3K) pathway is the most frequently altered signaling pathway in human cancers.
  • Recent Phase I studies demonstrate the feasibility and tolerability of PI3K pathway inhibitors in humans.
  • Early clinical evidence suggests anti-tumor activity of PI3K inhibitors in advanced cancer patients.

Purpose of the Study:

  • To evaluate the clinical feasibility and tolerability of PI3K pathway inhibitors.
  • To explore the anti-tumor activity of PI3K inhibitors in patients with advanced cancer.
  • To establish optimal parameters for PI3K inhibition and identify pharmacodynamic biomarkers.

Main Methods:

  • Phase I clinical studies of PI3K pathway inhibitors.
  • Assessment of pharmacological inhibition feasibility and tolerability.
  • Evaluation of anti-tumor activity and pharmacodynamic biomarkers.

Main Results:

  • Pharmacological inhibition of PI3K is feasible and well-tolerated in humans.
  • Clinical evidence of anti-tumor activity observed in patients with advanced cancer.
  • Further studies are required to determine optimal inhibition intensity, duration, and biomarkers.

Conclusions:

  • PI3K pathway inhibitors are a promising therapeutic strategy for cancer treatment.
  • Future trials should focus on patient populations with PI3K pathway alterations.
  • Combination therapies involving PI3K inhibitors may enhance efficacy.

More Related Videos

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation10:52

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation

Published on: January 6, 2016

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...